课题基金 / 基金详情

Regulation of Innate Immunity by Pyrin Proteins

Regulation of Innate Immunity by Pyrin Proteins
Pyrin 蛋白对先天免疫的调节
批准号:
8288318
负责人:
JONATHAN A HARTON
金额:
$34.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2015-06-30

项目摘要

项目成果

JONATHAN A HARTON的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 TLR和NLR家族成员的细胞外和细胞内病原体识别启动先天 免疫和炎症反应。TLRs和NLRs都激活了NF-kB和MAPK信号通路 导致多种炎性细胞因子(如肿瘤坏死因子、白介素6和白介素8)的转录和分泌。不像 TLRs,NLRs还可以激活多蛋白炎症体复合体,使proIL-1和proIL-18处理为 它们的活跃形式。在不到五年的时间里,NLRs与遗传性自体炎症性疾病和 对越来越多的病原体的先天免疫反应,包括炭疽杆菌、鼠疫耶尔森菌、 和图拉氏方济氏菌。含有NLR蛋白的比林相互作用导致炎性小体组装 与ASC(带有卡片的凋亡斑点蛋白)一起募集和激活Caspase-1。这个 炎性小体复合体也可能参与诱导一种形式的caspase-1依赖的细胞凋亡。ASC 与NLRs和蛋白质派林的相互作用也可以激活核因子-kB。最近,只有吡喃的发现 同时影响核因子-kB和炎症体功能的蛋白质(POP)为宿主提供了一条途径 对促炎反应及其病原体颠覆的调节。这样做的长期目标是 建议理解仅依赖于吡喃的先天免疫反应的分子调控。 蛋白质。此外,对炎症体调节的理解将扩展到宿主与病原体的相互作用。 炎症小体功能或颠覆被证明是免疫或疾病的关键。 具体地说,我们已经确定了第二个人类POP(POP2),它抑制NF-kB p65的活性,与 ASC,并阻止一些NLR激活的炎性小体的激活。我们将检验这一假设 POP2通过干扰炎症体-2来负向调节促炎反应。 介导caspase-1激活和减弱核因子-kB信号,从而抑制有害的炎症 以及防止或减少先天性免疫反应中巨噬细胞的死亡。组合体宽广 基于分子和体内的方法,我们将解决以下目标:1)建立分子基础 针对POP2对核因子-kB的抑制2)建立POP2调节炎症体的分子基础 激活。3)确定POP2在体内调节炎性先天免疫反应中的作用。
英文摘要
SUMMARY Extracellular and intracellular pathogen recognition by members of the TLR and NLR families initiate innate immune and inflammatory responses. TLRs and NLRs both activate the NF-kB and MAPK signaling pathways leading to the transcription and secretion of multiple inflammatory cytokines (e.g. TNF¿, IL-6, and IL-8). Unlike TLRs, NLRs can also activate multiprotein inflammasome complexes that processes proIL-1¿ and proIL-18 to their active forms. In less than five years, NLRs have been linked to hereditary autoinflammatory diseases and innate immune response towards a growing number of pathogens, including Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Inflammasome assembly results from interaction of a pyrin containing NLR protein with ASC (apoptotic speck protein with a CARD) followed by recruitment and activation of Caspase-1. The inflammasome complex may also be involved in inducing a form of caspase-1 dependent apoptosis. ASC interactions with NLRs and the protein Pyrin can also activate NF-kB. Recently, the discovery of pyrin only proteins (POPs) that influence both NF-kB and inflammasome functions has suggested an avenue for host regulation of the proinflammatory response and pathogen subversion thereof. The long-term objective of this proposal is to understand the molecular regulation of innate immune responses dependent upon pyrin only proteins. Further, understanding of inflammasome regulation will be extended to host-pathogen interactions where inflammasome function or subversion is demonstrated to be critical for immunity or disease. Specifically, we have identified a second human POP (POP2) which inhibits NF-kB p65 activity, interacts with ASC, and prevents the activation of a number of NLR activated inflammasomes. We will test the hypothesis that POP2 negatively regulates proinflammatory responses by interfering with both inflammasome- mediated caspase-1 activation and attenuating NF-kB signals, thus dampening harmful inflammation and preventing or reducing macrophage death during innate immune responses. Combining broad based molecular and in vivo approaches, we will address the following aims: 1) Establish the molecular basis for NF-kB inhibition by POP2 2) Establish the molecular basis for POP2 regulation of inflammasome activation. 3) Establish the in vivo role of POP2 in modulating inflammatory innate immune responses.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
The CLRX.1/NOD24 (NLRP2P) pseudogene codes a functional negative regulator of NF-κB, pyrin-only protein 4.
CLRX.1/NOD24(NLRP2P)假元代码NF-κB的功能负调节剂,仅吡啶蛋白4。
DOI: 10.1038/gene.2014.30
发表时间: 2014-09
期刊: Genes and immunity
影响因子: 5
作者: []
通讯作者:
DOI: 10.3389/fimmu.2013.00275
发表时间: 2013-09-17
期刊: Frontiers in immunology
影响因子: 7.3
作者: [Le HT, Harton JA]
通讯作者: Harton JA
POP2 as a novel therapeutic in rheumatoid arthritis
  • 批准号:
    10709887
  • 项目类别:
  • 资助金额:
    $17.93万
  • 财政年份:
    2022
  • 负责人:
    JONATHAN A HARTON
  • 依托单位:
POP2 as a novel therapeutic in rheumatoid arthritis
  • 批准号:
    10524468
  • 项目类别:
  • 资助金额:
    $21.52万
  • 财政年份:
    2022
  • 负责人:
    JONATHAN A HARTON
  • 依托单位:
Tools to evaluate POP2 as a regulator of arthritis
  • 批准号:
    10116275
  • 项目类别:
  • 资助金额:
    $8.15万
  • 财政年份:
    2020
  • 负责人:
    JONATHAN A HARTON
  • 依托单位:
Tools to evaluate POP2 as a regulator of arthritis
  • 批准号:
    9979151
  • 项目类别:
  • 资助金额:
    $8.13万
  • 财政年份:
    2020
  • 负责人:
    JONATHAN A HARTON
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: